[1] |
Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3): 229-263.
|
[2] |
Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics,2022[J].CA Cancer J Clin, 2022, 72(1): 7-33.
|
[3] |
张希, 杨雷, 刘硕, 等.2022 年全球恶性肿瘤统计报告解读[J].中华肿瘤杂志, 2024, 46(7): 710-721.
|
[4] |
郑荣寿, 陈茹, 韩冰峰, 等.2022 年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2024, 46(3): 221-231.
|
[5] |
Lang D, Ciombor KK.Diagnosis and management of rectal cancer in patients younger than 50 years: rising global incidence and unique challenges[J].J Natl Compr Canc Netw, 2022, 20(10):1169-1175.
|
[6] |
杨明, 张金珠, 王锡山.全国肿瘤登记中心发布的2013 年至2022 年结直肠癌流行数据趋势解读[J/OL].中华结直肠疾病电子杂志, 2024, 13(3): 177-181.
|
[7] |
李佳莹, 王旭丹, 梁雪, 等.1990~2021 年中国结直肠癌死亡趋势分析[J/OL].中华结直肠疾病电子杂志, 2024, 13(4): 274-279.
|
[8] |
Zeng H, Chen W, Zheng R, et al.Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health, 2018, 6(5): e555-e567.
|
[9] |
蔡三军.概论//蔡三军,章真,杜祥.循证结直肠肛管肿瘤学[M].上海:上海科学技术出版社,2016: 1-5.
|
[10] |
Edwards BK, Ward E, Kohler BA, et al.Annual report to the nation on the status of cancer, 1975~2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates[J].Cancer, 2010, 116(3): 544-573.
|
[11] |
Allemani C, Weir HK, Carreira H, et al.Global surveillance of cancer survival 1995~2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD -2)[J].Lancet, 2015, 385(9972): 977-1010.
|
[12] |
Allemani C, Matsuda T, Di Carlo V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet, 2018, 391(10125): 1023-1075.
|
[13] |
Zeng H, Zheng R, Sun K, et al.Cancer survival statistics in China 2019-2021: A multicenter, population-based study[J].J Natl Cancer Cent, 2024, 4(3): 203-213.
|
[14] |
王锡山.中美结直肠癌流行病学特征对比及防控策略分析[J/OL].中华结直肠疾病电子杂志, 2019, 8(1): 1-5.
|
[15] |
The Editorial Board of the Cancer Statistics in Japan.Cancer Statistics in Japan 2022[J].Tokyo: Foundation for Promotion of Cancer Research, 2022.
|
[16] |
Hashiguchi Y, Muro K, Saito Y, et al.Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer[J].Int J Clin Oncol, 2020, 25(1):1-42.
|
[17] |
中华医学会肿瘤学分会早诊早治学组.中国结直肠癌早诊早治专家共识(2023 版)[J/OL].中华普通外科学文献(电子版), 2024, 18(1): 1-3.
|
[18] |
刘正, 王锡山.国内外结直肠癌筛查的对比分析及启示[J/OL].中华结直肠疾病电子杂志, 2022, 11(1): 18-23.
|
[19] |
赵长林, 孙哲, 江洋深.谈如何应对影响中国结直肠癌筛查与早诊早治的因素与障碍[J/OL].中华普通外科学文献(电子版),2023, 17(5): 321-325.
|
[20] |
Kodeda K, Derwinger K, Gustavsson B, et al.Local recurrence of rectal cancer: A population-based cohort study of diagnosis,treatment and outcome[J].Colorectal Dis, 2012,14(5): e230-e237.
|
[21] |
Ponz de Leon M, Sant M, Micheli A, et al.Clinical and pathologic prognostic indicators in colorectal cancer.A population-based study[J].Cancer, 1992, 69: 626-635.
|
[22] |
Cawthorn SJ, Parums DV, Gibbs NM, et al.Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer[J].Lancet, 1990, 335(8697):1055-1059.
|
[23] |
Parikh AR, Van Seventer EE, Siravegna G, et al.Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer[J].Clin Cancer Res, 2021,27(20): 5586-5594.
|
[24] |
汪毅, 王杰, 许东奎, 等.Ⅰ期结直肠癌局部复发与转移19例患者的临床病理特征分析[J/OL].中华结直肠病电子杂志,2016, 5(6): 503-506.
|
[25] |
Saito N,Sugito M,Ito M, et al.Oncologic outcome of intersphincteric resection for very low rectal cancer[J].World J Surg, 2009, 33(8): 1750-1756.
|
[26] |
Ito M, Saito N, Sugito M, et al.Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer[J].Dis Colon Rectum, 2009, 52(1): 64-70.
|
[27] |
Quirke P, Dixon MF.The prediction of local recurrence inrectal adenocarcinoma by histopathological examination[J].Int J Colorectal Dis, 1988, 3(2): 127-131.
|
[28] |
顾晋, 丁长民.结直肠外科近年进展及热点[J].中华普通外科杂志, 2024, 39(1): 6-13.
|
[29] |
国家卫生健康委员会医政司, 中华医学会肿瘤学分会.国家卫生健康委员会中国结直肠癌诊疗规范(2023 版)[J].中华胃肠外科杂志, 2023, 26(6): 505-528.
|
[30] |
Chen G, Zeng Y, Feng C, et al.Tumor-informed patient-specific MRD monitoring analysis in colorectal cancer[J].J Clin Oncol,2023, 41(4_suppl): 48.
|
[31] |
顾睿祈, 方洪生, 蔡国响.循环肿瘤DNA 检测在结直肠癌诊治中的应用与进展[J/OL].中华结直肠疾病电子杂志, 2023,12(6): 453-459.
|
[32] |
Zou D, Day R, Cocadiz JA, et al.Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer[J].Carcinogenesis, 2020, 41(11):1507-1517.
|
[33] |
Adam IJ, Mohamdee MO, Martin IG, et al.Role of circumferential margin involvement in the local recurrence of rectal cancer[J].Lancet, 1994, 344(8924): 707-711.
|
[34] |
Quirke P, Durdey P, Dixon MF, et al.Local recurrence of rectal adenocarcinoma due to inadequate surgical resection.Histopathological study of lateral tumour spread and surgical excision[J].Lancet, 1986, 2(8514): 996-999.
|
[35] |
楼征, 张卫.结直肠肿瘤手术的质量控制[J].中华胃肠外科杂志, 2024, 27(6): 559-563.
|
[36] |
孙凌宇.从日本《大肠癌处理规约》和《大肠癌治疗指南》看结直肠癌诊治发展趋势[J].中国实用外科杂志, 2020, 40(3):267-270.
|
[37] |
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)结直肠癌诊疗指南2024 [M].北京:人民卫生出版社, 2024.
|
[38] |
Cinciripini PM, Kypriotakis G, Blalock JA, et al.Survival outcomes of an early intervention smoking cessation treatment after a cancer diagnosis[J].JAMA Oncol, 2024, 10(12): 1689-1696.
|
[39] |
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院, 北京协和医学院肿瘤医院, 《中华健康管理学杂志》编辑委员会, 等.防癌体检结直肠癌筛查技术应用专家共识[J].中华健康管理学杂志, 2024, 18(11): 805-815.
|
[40] |
Peng F, Lu J, Su K, et al.Oncogenic fatty acid oxidation senses circadian disruption in sleep-deficiency-enhanced tumorigenesis[J].Cell Metab, 2024, 36(7): 1598-1618.
|
[41] |
Hatime Z, El Kinany K, Huybrechts I, et al.Association of physical activity and sedentary behavior with colorectal cancer risk in Moroccan adults: A large-scale, population-based case-control study[J].Asian Pac J Cancer Prev, 2022, 23(6): 1859-1866.
|
[42] |
Wu C, Yang F, Zhong H, et al.Obesity-enriched gut microbe degrades myo-inositol and promotes lipid absorption[J].Cell Host Microbe, 2024, 32(8): 1301-1314.
|
[43] |
Lawler T, Walts ZL, Steinwandel M, et al.Type 2 diabetes and colorectal cancer risk[J].JAMA Netw Open, 2023, 6(11):e2343333.
|
[44] |
Ghimire J, Collins ME, Snarski P, et al.Obesity-facilitated colon cancer progression is mediated by increased diacylglycerol O-acyltransferases 1 and 2 levels[J].Gastroenterology, 2024:S0016-5085(24)05464-7.
|
[45] |
Fu Y, Guo X, Sun L, et al.Exploring the interplay of diet, obesity,immune function, and cancer[J].Cancer Discov, 2024, 14(11):2047-2050.
|
[46] |
Roje B, Zhang B, Mastrorilli E, et al.Gut microbiota carcinogen metabolism causes distal tissue tumours[J].Nature, 2024,632(8027): 1137-1144.
|
[47] |
Eng C, Yoshino T, Ruíz-García E, et al.Colorectal cancer[J].Lancet, 2024, 404(10449): 294-310.
|
[48] |
Swanton C, Bernard E, Abbosh C, et al.Embracing cancer complexity: hallmarks of systemic disease[J].Cell, 2024, 187(7):1589-1616.
|
[49] |
刘睿清, 卢云.基于循证医学的早期结肠癌外科治疗进展[J].中华胃肠外科杂志, 2022, 25(12): 1144-1149.
|
[50] |
Li M, Hu M, Jiang L, et al.Trends in cancer incidence and potential associated factors in China[J].JAMA Netw Open, 2024,7(10): e2440381.
|
[51] |
国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中华肿瘤杂志, 2021, 43(1): 16-38.
|
[52] |
中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会结直肠肿瘤专业委员会腹腔镜专业委员会, 中华医学会外科学分会结直肠外科学组, 等.中国直肠癌侧方淋巴结转移诊疗专家共识(2024 版)[J].中华胃肠外科杂志, 2024,27(1): 1-14.
|
[53] |
Guan X, Hu X, Jiang Z, et al.Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES)for colorectal cancer in China: A national database study of 5 055 patients[J].Sci Bull (Beijing), 2022, 67(13): 1331-1334.
|
[54] |
Zhang J, Chi P, Shi L, et al.Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the FOWARC study after a median follow-up of 10 years[J].J Clin Oncol, 2024: JCO2401676.
|
[55] |
赵长林.结直肠癌肝转移转化治疗的相关问题[J/OL].中华普通外科学文献(电子版), 2014, 8(3): 181-184.
|
[56] |
中华医学会病理学分会, 国家病理质控中心.实体瘤分子残留病灶检测共识[J].中华病理学杂志, 2024, 53(11): 1088-1096.
|
[57] |
Kotani D, Oki E, Nakamura Y, et al.Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer[J].Nat Med, 2023, 29(1): 127-134.
|
[58] |
Mo S, Ye L, Wang D, et al.Early detection of molecular residual disease and risk stratification for stage to Ⅲ colorectal cancer via circulating tumor DNA methylation[J].JAMA Oncol, 2023, 9(6):770-778.
|
[59] |
Liu W, Jin KM, Zhang MH, et al.Recurrence prediction by circulating tumor DNA in the patient with colorectal liver metastases after hepatectomy: A prospective biomarker study[J].Ann Surg Oncol, 2023, 30(8): 4916-4926.
|